Minimal residual disease detection in human leukemias: biologic and clinical significance.
The very rapid development of techniques based on use of the polymerase chain reaction (PCR) for characterizing molecular lesions in leukaemia and lymphoma mow offers the opportunity for monitoring residual disease at a sensitivity of one malignant cell in 10(5) or 10(6) normal cells. Maximal specificity is achieved when the DNA sequences amplified are truly leukaemia-specific (i.e. BCR/ABL in CML, PML/RAR-alfa in APL, AML1/ETO in t(8; 21) AML and CBFB/MYH1 in inv(16) AML). A good level of sensitivity may also be achieved by using immunoglobin heavy chain (IGH) and T-cell receptor (TCR) gene rearrangements if a clonospecific probe can be generated. For clinical purposes the crucial issues are the following: can PCR techniques be used for confirmation of diagnosis and evaluation of extent of disease? Can PCR data obtained be developed to quantitate the PCR product and thereby increase its predictive value? These and other issues are still a matter of debate and several studies are presently in progress to address these points.
Saglio
G
G
Dipartimento di Scienze Biomediche e Oncologia Umana, Università di Torino, Ospedale San Luigi Gonzaga, Orbassano-Torino, Italy.
D016026:Bone Marrow Transplantation / Q000276:immunology; D004273:DNA, Neoplasm / Q000032:analysis*; D006801:Humans; D007938:Leukemia / Q000235:genetics*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics; D015470:Leukemia, Myeloid, Acute / Q000235:genetics; D015473:Leukemia, Promyelocytic, Acute / Q000235:genetics; D018365:Neoplasm, Residual; D016133:Polymerase Chain Reaction; D012008:Recurrence; D012680:Sensitivity and Specificity
D004273:DNA, Neoplasm